Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Fundamental Analysis

NASDAQ:AMRN - US0231114044 - ADR

15.33 USD
+0.3 (+2%)
Last: 9/5/2025, 8:00:01 PM
Fundamental Rating

3

Overall AMRN gets a fundamental rating of 3 out of 10. We evaluated AMRN against 542 industry peers in the Biotechnology industry. While AMRN seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, AMRN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year AMRN has reported negative net income.
In the past year AMRN has reported a negative cash flow from operations.
In the past 5 years AMRN reported 4 times negative net income.
In the past 5 years AMRN reported 4 times negative operating cash flow.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

AMRN's Return On Assets of -15.46% is amongst the best of the industry. AMRN outperforms 81.00% of its industry peers.
Looking at the Return On Equity, with a value of -22.28%, AMRN belongs to the top of the industry, outperforming 83.21% of the companies in the same industry.
Industry RankSector Rank
ROA -15.46%
ROE -22.28%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

The Gross Margin of AMRN (54.10%) is better than 76.38% of its industry peers.
In the last couple of years the Gross Margin of AMRN has declined.
AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

6

2. Health

2.1 Basic Checks

AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMRN has more shares outstanding than it did 1 year ago.
AMRN has more shares outstanding than it did 5 years ago.
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -1.79, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.79, AMRN is in line with its industry, outperforming 53.32% of the companies in the same industry.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.79
ROIC/WACCN/A
WACC7.49%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AMRN has a Current Ratio of 3.26. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN has a Current ratio of 3.26. This is in the lower half of the industry: AMRN underperforms 60.89% of its industry peers.
A Quick Ratio of 2.34 indicates that AMRN has no problem at all paying its short term obligations.
AMRN's Quick ratio of 2.34 is on the low side compared to the rest of the industry. AMRN is outperformed by 68.08% of its industry peers.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 2.34
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for AMRN have decreased strongly by -18.75% in the last year.
AMRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -17.17%.
AMRN shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -11.86% yearly.
EPS 1Y (TTM)-18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1074.71%
Revenue 1Y (TTM)-17.17%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%7.78%

3.2 Future

The Earnings Per Share is expected to grow by 17.76% on average over the next years. This is quite good.
AMRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.83% yearly.
EPS Next Y-13.13%
EPS Next 2Y21.56%
EPS Next 3Y16.69%
EPS Next 5Y17.76%
Revenue Next Year-4.55%
Revenue Next 2Y-8.82%
Revenue Next 3Y-6.09%
Revenue Next 5Y26.83%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AMRN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15 20

4.3 Compensation for Growth

AMRN's earnings are expected to grow with 16.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.56%
EPS Next 3Y16.69%

More info and screens

0

5. Dividend

5.1 Amount

AMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMARIN CORP PLC -ADR

NASDAQ:AMRN (9/5/2025, 8:00:01 PM)

15.33

+0.3 (+2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2025-07-30/bmo
Earnings (Next)10-28 2025-10-28
Inst Owners17.64%
Inst Owner Change-91.67%
Ins Owners0.77%
Ins Owner Change0.61%
Market Cap317.07M
Analysts42.5
Price Target11.22 (-26.81%)
Short Float %2.08%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)217.77%
Min EPS beat(2)-30.72%
Max EPS beat(2)466.25%
EPS beat(4)2
Avg EPS beat(4)115.68%
Min EPS beat(4)-30.72%
Max EPS beat(4)466.25%
EPS beat(8)5
Avg EPS beat(8)81.97%
EPS beat(12)7
Avg EPS beat(12)66.33%
EPS beat(16)9
Avg EPS beat(16)43.98%
Revenue beat(2)1
Avg Revenue beat(2)6.91%
Min Revenue beat(2)-18.83%
Max Revenue beat(2)32.65%
Revenue beat(4)2
Avg Revenue beat(4)19.27%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)16.14%
Revenue beat(12)8
Avg Revenue beat(12)11.62%
Revenue beat(16)9
Avg Revenue beat(16)6.62%
PT rev (1m)-31.25%
PT rev (3m)-18.52%
EPS NQ rev (1m)17.65%
EPS NQ rev (3m)2.67%
EPS NY rev (1m)-8.61%
EPS NY rev (3m)6.03%
Revenue NQ rev (1m)-1.41%
Revenue NQ rev (3m)-10.21%
Revenue NY rev (1m)7.37%
Revenue NY rev (3m)4.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.45
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.7
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-1.15
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS10.61
BVpS22.48
TBVpS21.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.46%
ROE -22.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.1%
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 2.34
Altman-Z -1.79
F-Score3
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1074.71%
EPS Next Y-13.13%
EPS Next 2Y21.56%
EPS Next 3Y16.69%
EPS Next 5Y17.76%
Revenue 1Y (TTM)-17.17%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%7.78%
Revenue Next Year-4.55%
Revenue Next 2Y-8.82%
Revenue Next 3Y-6.09%
Revenue Next 5Y26.83%
EBIT growth 1Y-90.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year21.04%
EBIT Next 3Y18.17%
EBIT Next 5YN/A
FCF growth 1Y32.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.99%
OCF growth 3YN/A
OCF growth 5YN/A